Cangrelor

Cangrelor (trade name Kengreal in the US and Kengrexal in Europe) is a P2Y₁₂ inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y₁₂ inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion.

单词	Cangrelor
释义	Cangrelor 英语百科 Cangrelor Cangrelor (trade name Kengreal in the US and Kengrexal in Europe) is a P2Y₁₂ inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y₁₂ inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion.
随便看	yMLH1 gene YMMD YMMV YMN YMODEM Ymodem Ymodem Ymonville Y motif ymounted YMP Ympe YMPN ymr ymston YMT YMTWTM ymut YMV15 YMW YMXM sequence YMY ymyd Yn ynag period exercise Ynag Promoting Decoction